Search

As an important component of mechanical transmission systems, internal splines are widely used in aerospace, industrial equipment, and other fields. However, internal splines are prone to deformation and shrinkage after heat treatment. At present, most internal splines with a pitch circle diameter greater than φ60 mm can be processed and shaped by ordinary corundum grinding wheels, but there is no effective processing method for the shaping of small- and medium-sized internal splines. This paper establishes a single abrasive material removal model; uses Abaqus to simulate three-body free grinding; and analyzes the effects of abrasive rotation angle, rotation speed, and grinding depth on material removal under different conditions. By comparing the tooth lead deviation and tooth direction deviation before and after internal spline grinding, the experimental results show that after ultrasonic vibration grinding, the internal spline tooth profile deviation is reduced by 41.9%, and the tooth direction deviation is reduced by 44.1%, which provides a new processing method for the deformation recovery of internal splines after heat treatment. [ABSTRACT FROM AUTHOR]

There are no standard third-line or beyond treatments for patients with driver mutation-positive advanced lung adenocarcinoma (LUAD). Anlotinib was approved as a third-line multitarget drug in China in 2018. Limited data are available regarding the efficacy and safety of anlotinib compared with chemotherapy. To investigate the efficacy and safety of anlotinib compared with traditional chemotherapy in patients with epidermal growth factor receptor (EGFR)-positive advanced LUAD. We conducted a retrospective study of 83 EGFR mutation-positive patients with advanced LUAD between 2011 and 2022. Progression-free survival (PFS) and overall survival (OS) were the primary endpoints, whereas the objective response rate (ORR) and disease control rate (DCR) were the secondary endpoints. Anlotinib-related adverse events (AEs) were recorded to evaluate the safety of anlotinib. 39 patients with LUAD received anlotinib and 44 patients with LUAD received chemotherapy were enrolled in the study. Patients treated with anlotinib exhibited longer PFS (11.2 vs 4.5 months, P <.01) and OS (18.8 vs 15.8 months, P <.05) than patients treated with chemotherapy. There were no significant differences in ORR (7.9% vs 20.5%, P =.129) or DCR (100% vs 93.2%, P =.120) between the two groups. Anlotinib-related AEs grading 3-4 level were observed in 2 (5.1%) patients, no anlotinib-related death was recorded. Cox regression analyses of PFS and OS showed that brain metastases and age < 30 years at diagnosis had negative effects on clinical outcomes. Anlotinib is effective and safe in patients with EGFR-positive advanced LUAD. Patients without brain metastases had better clinical outcomes. [ABSTRACT FROM AUTHOR]